RxDoctor Payments DataLook up a doctor →

William Mihalko, MD

Orthopaedic Surgery · Charlottesville, VANPI 1013086644

Payments from drug & device makers

$2,140,673in general payments, 2019–2025

Across 207 payments — averaging $10,341 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aesculap AG$1.6M
  • Aesculap Implant Systems, LLC$281K
  • Medacta USA, Inc.$126K
  • Pacira Pharmaceuticals Incorporated$50K
  • Aesculap, Inc.$30K
  • Pacira Cryotech Incorporated$11K
  • plus $8K from 10 others
$75in research payments, 2019–2025

Across 1 payment — averaging $74.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Aesculap Implant Systems, LLC$75

What the payments were for

  • Royalty or licence$1,633,21982%
  • Consulting fees$274,63214%
  • Speaking & faculty fees$66,2933%
  • Travel & lodging$21,1161%
  • Food & beverage$4,1160%
  • Education$960%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,140,673 in reported general payments places this provider in the 95th percentile of 473 orthopaedic surgery providers in Virginia.

See all orthopaedic surgery providers in Virginia

Medicare billing

Part B allowed, 2024
$182,434
Medicare patients
418
Services billed
7,162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Methylprednisolone114$822
Celecoxib15$256
Meloxicam55$183
Gabapentin12$155
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen15$92
Tramadol Hcl24$81
Oxycodone Hcl11$75
Naproxen16$56
Cephalexin11$29
Ondansetron Hcl15$27

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →